Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

11.1%

5 terminated out of 45 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed with results

Key Signals

7 with results75% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (9)
Early P 1 (2)
P 1 (22)
P 2 (6)
P 3 (1)

Trial Status

Completed15
Active Not Recruiting11
Recruiting5
Terminated5
Unknown5
Withdrawn3

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT01552434Phase 1Active Not RecruitingPrimary

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT04067336Phase 1RecruitingPrimary

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT05861947Phase 1Terminated

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

NCT03671226Not ApplicableActive Not RecruitingPrimary

Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

NCT04053517Active Not RecruitingPrimary

Financial Distress in Advanced Cancer Patients

NCT03525873Phase 3Active Not RecruitingPrimary

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

NCT02491632Phase 2Active Not RecruitingPrimary

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

NCT03021486Phase 2Active Not RecruitingPrimary

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

NCT04585750Phase 1Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04119037Not ApplicableActive Not RecruitingPrimary

Cordotomy in Reducing Pain in Patients With Advanced Cancer

NCT03203525Phase 1Active Not RecruitingPrimary

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT03707574CompletedPrimary

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03287492Not ApplicableActive Not RecruitingPrimary

RCT of QPS vs General Information Sheet

NCT02286687Phase 2Active Not RecruitingPrimary

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT03069469Phase 1Active Not RecruitingPrimary

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT01582191Phase 1CompletedPrimary

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

NCT05997342Phase 1CompletedPrimary

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

NCT06872489Unknown

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

NCT06344351Phase 1CompletedPrimary

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

NCT04503265Phase 1RecruitingPrimary

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Scroll to load more

Research Network

Activity Timeline